Last week’s hot topic on pulmonary fibrosis was OFEV’s Effectiveness as IPF Treatment Confirmed in Analysis of Pooled Clinical Trial Data written by Margarida Azevedo.
This article is about combined evidence from the TOMORROW and INPULSIS clinical trials that confirm the safety and efficacy of OFEV (nintedanib, Boehringer Ingelheim) in slowing disease progression and greatly reducing acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF), a study reported.
The article detailing the pooled analyses of the clinical studies, “Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials,” was published in the journal Respiratory Medicine.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?